Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Macerich Company (The) Common Stock (MAC) vs Relay Therapeutics Inc. Common Stock (RLAY) Price & Performance

Macerich Company (The) Common StockTrade
Relay Therapeutics Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Macerich Company (The) Common Stock vs Relay Therapeutics Inc. Common Stock — how do they compare? Macerich Company (The) Common Stock trades at $22.18 (market cap $6.39B), while Relay Therapeutics Inc. Common Stock trades at $17.07 (market cap $3.81B). The key difference: Macerich Company (The) Common Stock is the larger of the two by market cap, and Macerich Company (The) Common Stock pays a 3.02% dividend while Relay Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Macerich Company (The) Common Stock for 0 Days and Relay Therapeutics Inc. Common Stock for 5 Days on average.

MACRLAY
Market Cap
$6.39B$3.81B
Volume
2,684,1511,706,150
Sector
Real EstateHealth
52-Week High
$26.51$20.75
52-Week Low
$16.20$6.05
Typical Hold Time
0 Days5 Days
Enterprise Value
$11.07B$2.93B
Dividend Yield
3.02%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Macerich Company (The) Common Stock

No Aura AI signal available yet.

Relay Therapeutics Inc. Common Stock

Relay Therapeutics (RLAY) trades at $17.36, down 3.45% today, with technical indicators showing bearish momentum. The company remains in clinical-stage development with negative profitability metrics, including a -2,763.64% net income margin and -$276.48M net loss for 2025. Recent Q2 2026 earnings missed expectations with a loss of $0.41 per share, though the company continues advancing its oncology pipeline with Phase 3 trials planned for 2027.

Despite unanimous analyst buy ratings and a $26.25 consensus price target representing 51% upside, RLAY faces significant execution risk as a pre-revenue biotech. The stock's bearish technical setup and persistent cash burn require careful risk management, though institutional accumulation and AI-driven drug discovery platform provide long-term potential.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MAC
100% Buy0% Sell
Avg holding period · 0 Days
RLAY

No sentiment data available yet.

Top news

Latest headlines on both assets

About Macerich Company (The) Common Stock

The Macerich Company is a real estate investment trust that owns, operates, and redevelops shopping centers concentrated in California, the Pacific Northwest, and other major US markets.

Read more on MAC →

About Relay Therapeutics Inc. Common Stock

Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.

Read more on RLAY →